Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 75% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work, and whether you can afford to take the high risk of losing your money. Professional clients can lose more than they deposit.

 

All trading involves risk.

The value of shares, ETFs and ETCs bought through a share dealing account, a stocks and shares ISA or a SIPP can fall as well as rise, which could mean getting back less than you originally put in. Past performance is no guarantee of future results.

The information on this site is not directed at residents of the United States, Belgium or any particular country outside the UK and is not intended for distribution to, or use by, any person in any country or jurisdiction where such distribution or use would be contrary to local law or regulation.

Guardian Stockbrokers Limited is authorised and regulated by the Financial Conduct Authority (No. 492519).

Registered office: 14 City Road, London EC1Y 2AA. Registered in England and Wales. Company No. 06756375. 

Top 5 AIM shares

Burford Capital

The World's largest provider of arbitration and litigation finance

 

Burford Capital was founded in 2009 when its chief executive Christopher Bogart wielded funds raised from working as general counsel to Time Warner on its merger with AOL. The company was a pioneer in providing institutional-quality commercial litigation finance and aims to 'address the impact of unequal financial resources on litigation outcomes'.

The company’s income is derived from providing litigation finance as well as risk management and asset recovery services to its clients and law firms around the world.

Listed on AIM                                         21 October 2009

Listing Price                                           100p

Listing Market Capatalisation          £80,000,000

Highest price since list                       2075p (29 August 2018)

% Return of                                           1975%        

FEVER-TREE Drinks

The upmarket mixer maker

 

Fevertree Drinks, which produces premium mixers for alcoholic beverages, has been a soaring success since listing in 2014, having more than trebled in value since the middle of 2016.

 

The company has triumphed off the back of the booming market for premium spirits, starting with gin and gradually moving to dark rum and others.

Fevertree is the most popular mixer brand in the UK off-trade (supermarkets and stores) and it is still growing its position in on-trade (pubs and restaurants). It is also expanding in both the US and Europe.

Listed on AIM                                         7 November 2014

Listing Price                                           134p

Listing Market Capatalisation          £154,000,000

Highest price since list                        4242p (12 September 2018)

% Return of                                            3066%   

Hutchinson China MediTech

The biopharma and pharma stock

 

Hutchinson China MediTech is a biopharmaceutical company pursuing treatments for oncology and immunological diseases. It currently generates revenue by manufacturing and distributing prescription drugs and other health products to consumers in China.

 

It is majority-owned by CK Hutchison Holdings Limited, a conglomerate with annual sales of over $500 billion.

Listed on AIM                                        19th May 2006

Listing Price                                           275p

Listing Market Capatalisation          £140,000,000

Highest price since list                       5940p* (4th January 2018) *Share split of 1 for 10, May 3 2019

% Return of                                           2060%

ASOS

Fast fashion for millennials

 

ASOS has been one of the biggest beneficiaries of the transition to online shopping that has left bricks-and-mortar retailers struggling. The online fashion retailer has continued to deliver growth in its core UK market as well as expansionary geographies in the US and Europe, but it has seen a slowdown.

Listed on AIM                                        3rd May 2001

Listing Price                                           20p

Listing Market Capatalisation          £12,323,952

Highest price since list                       7776p* (15th March 2018) 

% Return of                                           38,780%

Abcam

A profitable biopharma business

 

Abcam plc is a global life sciences company. Abcam plc is both the UK operating company and the holding company for the group. There are a number of trading subsidiaries which are 100 percent owned by Abcam plc.

Abcam is a producer, distributor, and seller of high-quality protein research tools. These tools enable life scientists to analyse components of living cells at the molecular level which is essential in a wide range of fields including drug discovery, diagnostics and basic research. They are headquartered in Cambridge, UK with ten additional locations across Asia, the UK and the USA.

Listed on AIM                                        3rd November 2005

Listing Price                                           167p

Listing Market Capatalisation          £57,500,000

Highest price since list                       8950p* (15th September 2010) *Share split of 1 for 5, Nov 15 2010

% Return of                                           5259%